Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$4.17 USD
-0.12 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRVS 4.17 -0.12(-2.80%)
Will CRVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVS
Corvus Pharmaceuticals Q2 2025 Earnings Preview
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News
Corvus announces IND application approved by CDE of China NMPA to start trial
Corvus announces IND application approved by CDE of China NMPA to start trial
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)